Endothelin and heart failure

被引：25

作者：

Nambi P. ^{[1
]}

Clozel M. ^{[2
]}

Feuerstein G. ^{[1
]}

机构：

[1] Cardiovascular Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE

[2] Actelion Ltd., Allschwil

来源：

Heart Failure Reviews | 2001年 / 6卷 / 4期

关键词：

Bosentan; Congestive heart failure; Endothelin; Endothelin receptors;

D O I：

10.1023/A:1011464510857

中图分类号：

学科分类号：

摘要：

The availability of potent and orally active nonpeptide endothelin (ET) receptor antagonists has generated a host of information on the pathophysiological role of ET-1 in a number of preclinical models including hypertension, renal failure, heart failure and pulmonary hypertension. Convincing data are available to show that ET-1 receptor antagonists are beneficial in humans as far as reversal of deranged systemic and regional hemodynamics associated with CHF and pulmonary hypertension. As in other disease areas, the issue of whether ETA-selective or ETA/B antagonists are more suited for CHF treatment remains unresolved. ETB receptors may mediate some critical processes in the kidney such as sodium and water excretion in addition to releasing vasodilator substances such as NO and prostacyclin from endothelial cells. In heart failure and chronic renal diseases, preservation of ETB-mediated responses in the kidney and pulmonary endothelium might be beneficial. On the other hand, blockade of ETB-mediated vasoconstriction, smooth muscle cell proliferation and fibrosis by ETB antagonists might be beneficial. In clinical trials so far, the hemodynamic effects of mixed antagonists of ET receptors and ETA selective antagonists seem equivalent.

引用

页码：335 / 340

页数：5

共 47 条

[1]

Inoue A., Yanagisawa M., Kimura S., Kasuga Y., Miyuchi T., The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes, Proc Natl Acad Sci, 86, pp. 2863-2867, (1989)

[2]

Simonson M., Dunn M., Cellular signalling by peptides of the endothelin gene family, FASEB J, 4, pp. 2989-3000, (1990)

[3]

Resink T., Scott-Burden T., Buhler F., Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells, Eur J Biochem, 189, pp. 415-421, (1990)

[4]

Liu Y., Geisburhler B., Jones A., Activation of multiple mechanisms including phospholipase D by endothelin-1 in rat aorta, Am J Physiol, 262, (1992)

[5]

Lonchampt M., Pinelis S., Goulin J., Chabrier P., Braquet P., Proliferation and Na+/H+ exchange activation by endothelin in vascular smooth muscle cells, Am J Hypertension, 4, pp. 776-779, (1991)

[6]

Wang Y., Rose P., Webb M., Dunn M., Endothelins stimulate mitogen activated protein kinase cascade through either ETA or ETB, Am J Physiol, 267, (1994)

[7]

Cazanbon S., Ramos-Morales F., Fischer S., Schweighoffer F., Strosberg A., Courand P., Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes, J Biol Chem, 269, pp. 24805-24809, (1994)

[8]

Kurihara Y., Kurihara H., Suzuki H., Kodama T., Maemura K., Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1, Nature, 36, pp. 703-710, (1994)

[9]

Hosada K., Hammer R., Giad A., Richardson J., Baynash A., Targeted and natural (piebald-lethal) mutations of endothelin B receptor gene produce megacolon associated with spotted coat color in mice, Cell, 79, pp. 1267-1276, (1994)

[10]

Puffenberger E., Hosada K., Washington S., Nakao K., DeWit D., A missense mutation of the endothelin B-receptor gene in multigenic Hirschsprung's disease, Cell, 79, pp. 1257-1266, (1994)

← 1 2 3 4 5 →